SRTCX1003

Cat. No.:	HY-124240
CAS No.:	1203480-86-7
Molecular Formula:	$C_{23}H_{23}N_5O_3S$
Molecular Weight:	449.53
Target:	Sirtuin
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SRTCX1003 is an orally active SIRT1 activator. SRTCX1003 suppresses inflammatory responses[1].
IC_{50} & Target	SIRT1[1]

In Vitro

SRTCX1003 (0-10 μM; 24 h) mediates a dose-dependent reduction of acetylated p65 protein in U2OS cells[1].
SRTCX1003 (5 μM; 6 h) attenuates TNFα-induced p65 acetylation in HEK 293T/17 cells[1].
SRTCX1003 (0-100 μM; 2 h) shows dose-dependent reduction of LPS (HY-D1056)-induced TNFα secretion from RAW cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot AnalysisHEK 293T/17

Cell Line:	HEK 293T/17
Concentration:	5 μM
Incubation Time:	6 h followed by 20 minutes TNFα stimulation
Result:	Significantly reduced TNFα-stimulated p65 acetylation.

In Vivo

SRTCX1003 (3-100 mg/kg; oral; once) decreases LPS (HY-D1056)-stimulated TNFα and IL-12p40 production in mice inflammation model[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c mice, LPS-induced inflammation mouse model[1]
Dosage:	3, 10, 30 and 100 mg/kg
Administration:	Oral, 60 minutes prior to LPS administration
Result:	Dose-dependently reduced LPS-stimulated TNFα and IL-12p40 production.

REFERENCES

[1]. Yang H, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA